pyrroles has been researched along with Kawasaki Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chahal, N; Manlhiot, C; McCrindle, BW; Niedra, E; Yeung, RS | 1 |
| Tremoulet, AH | 1 |
| Manlhiot, C; McCrindle, BW | 1 |
| Blankier, S; Ito, S; McCrindle, BW; Yeung, RS | 1 |
4 other study(ies) available for pyrroles and Kawasaki Disease
| Article | Year |
|---|---|
Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.
Topics: Administration, Oral; Anthropometry; Anti-Inflammatory Agents; Atorvastatin; Canada; Child; Child Development; Cholesterol; Coronary Aneurysm; Coronary Vessels; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver Function Tests; Male; Medical Records, Problem-Oriented; Mucocutaneous Lymph Node Syndrome; Pyrroles; Retrospective Studies | 2014 |
Comment on atorvastatin safety in kawasaki disease patients with coronary artery aneurysms.
Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles | 2014 |
Author reply to comment on "atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms".
Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles | 2014 |
The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.
Topics: Animals; Antigens, Bacterial; Arteritis; Atorvastatin; Cell Wall; Coronary Aneurysm; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lacticaseibacillus casei; Lymphocyte Activation; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mucocutaneous Lymph Node Syndrome; Pyrroles; Specific Pathogen-Free Organisms; Superantigens; Tumor Necrosis Factor-alpha | 2011 |